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EDITORIAL REVIEW
Current status of the use of 1,25(OH)2D3 in the management
of renal osteodystrophy
Renal failure is associated with many distur-
bances in the metabolism of divalent ions, and these
abnormalities have been collectively called renal
osteodystrophy." They may include hypocalcemia,
hyperphosphatemia, hypermagnesemia, skeletal re-
sistance to the calcemic action of parathyroid hor-
mone (PTH), defective intestinal absorption of cal-
cium, secondary hyperparathyroidism and elevated
blood levels of PTH, soft tissue calcification, and
bone disease [11. Many of these derangements
could be the direct results or the consequences of
vitamin D deficiency. For this reason vitamin D
compounds have been used to treat some of these
abnormalities [2-5]. It soon became obvious that
very large doses of the vitamin are required to im-
prove or correct certain components of renal osteo-
dystrophy [2, 6, 7]. This phenomenon has led to the
suggestion that a vitamin-D-resistant state exists in
patients with uremia.
Recent advances in the field of vitamin D metabo-
lism have shown that the parent vitamin undergoes
several metabolic changes, resulting in the forma-
tion of biologically active metabolites [8-12]. The
biologic activity of these metabolites has been stud-
ied with varying degrees of detail both in animals
[11-14] and humans [15-18]. Most attention was
given to the effects of 25-hydroxyvitamin D (25-OH-
D3) and 1,25 dihydroxyvitamin D (l,25[0H12D3)
[11-14] and more recently to 24,25 dihydroxyvita-
mm D (24,25[OH]2D3) [19, 20].
The most active vitamin D metabolite is 1,25
(OH)2D3, and it is made solely by the kidney [10, 21,
22]. Therefore, patients with chronic uremia and re-
duced functioning renal mass may not be able to
produce an adequate amount of 1,25(OH)2D3, and
therefore, a state of vitamin D deficiency could de-
velop. Indeed, the blood concentrations of
1 ,25(OH)2D3 in patients with advanced renal fail-
ure and those treated with dialysis are either very
low or undetectable [23]. These findings provided at
least a partial explanation for the concept of a vita-
min-D-resistant state in uremia and formed the
basis for the therapeutic rationale for the use of
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1,25(OH)2D3 in the management of the abnormal-
ities of divalent ion metabolism in patients with ad-
vanced renal failure.
Several lines of evidence indicate that a vitamin-
D-deficient state may even exist in patients with
early and moderate renal failure. First, skeletal re-
sistance to the calcemic action of PTH, which is at
least partly due to a deficiency in 1 ,25(OH)2D3 [24],
as demonstrated in nephrectomized dogs, is present
in patients with early renal failure [25]. Second, im-
paired intestinal absorption of calcium could be
demonstrated in patients with creatinine clearance
of 50 to 80 mllmin [26]. The authors found that 6 of
their 26 patients had low intestinal absorption of
calcium. Third, defective mineralization of osteoid
has been found in patients with a GFR greater than
50 mllmin [27]. It is interesting, however, that both
Slatopolsky et al [28] and ourselves (unpublished
observations) have found that the blood concentra-
tions of 1 ,25(OH)2D3 in such patients are either nor-
mal or mildly elevated. To reconcile between target
organ evidence for vitamin D deficiency and normal
blood concentrations of 1,25(OH)2D3, one can con-
clude that a vitamin-D-resistant state is present, and
supranormal blood concentrations of I ,25(OH)2D3
are needed to maintain normal function of the target
organs that require vitamin D for their metabolism.
Indeed, dietary phosphate restriction [29], a proce-
dure that may enhance the production of
1 ,25(OH)2D3 by the kidney, raised the blood con-
centrations of l,25(OH)2D3 in such patients and was
associated with reversal of the defects and abnor-
malities of the target organs (unpublished observa-
tions). The mechanisms of a vitamin-D-resistant
state in patients with early renal failure and the rea-
sons for the inability to raise their blood levels of
I ,25(OH)D3 are complex and not yet understood.
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These findings provide a rational basis for the ini-
tiation of 1 ,25(OH)2D3 therapy early in the course of
renal insufficiency. At present, the drug is not avail-
able for use in such patients, and its clinical efficacy
in patients with early renal failure needs to be dem-
onstrated by future investigation (see below).
It is important to emphasize at this point that
some or most of the beneficial effects of
I,25(OH)2D3 in the management of renal osteo-
dystrophy could be produced by other vitamin D
compounds, such as cholecalciferol [3, 30], dihy-
drotachysterol [2, 5], or 25-OH-D3 [15, 16]. The
smaller dose of 1,25(OH)2D3 that is needed to
achieve beneficial effects and its shorter half life
make it, however, a better and a safer agent than
are the other compounds. On the other hand, the
high biologic potency of 1,25(OH)2D3 causes the
early appearance of hazardous side effects with
even very small doses. Thus, close monitoring of
the patients receiving 1,25(OH)2D3 is mandatory.
A large number of studies have been performed
evaluating the effects of I ,25(OH)2D3 on divalent
ion metabolism in patients with advanced renal fail-
ure and those treated with hemodialysis. These re-
ports describe varying degrees of success in the
management of the different components of renal
osteodystrophy. These variations may be related to
differences in the pathologic lesions among the pa-
tients, the dose of the metabolite, the duration of
therapy, and the methods of assessment. Because
1,25(OH)2D3 is now available for general use in the
treatment of renal osteodystrophy in dialysis pa-
tients, it appears timely to review the available in-
formation on its effects and hazards in order to pro-
vide a critical analysis of the basis for its therapeu-
tic use.
The information in this editorial is based on data
published from November, 1972 (the first report on
clinical use of 1 ,25(OH)2D3), through July, 1979, and
it includes 30 reports [17, 18, 31—58]. These data de-
scribe the effects of 1,25(OH)2D3 in 57 patients with
chronic uremia and 208 dialysis patients. There
were 28 children among this patient population. We
emphasize, however, that the actual number of pa-
tients studied could be smaller because some pa-
tients may have been reported more than once. A
symposium dealing with the clinical use of
l,25(OH)2D3 was held in Chantecler, Quebec, Can-
ada, June, 1978. During this symposium, the inves-
tigators described their experiences with this vita-
min D metabolite. The reader is referred to the pro-
ceedings of this symposium [59].
Dosage
The dosage of l,25(OH)2D3 varied from 0.027 to
3.0 g!day. The dosage in the early studies was very
small (< 0.5 pg/day), but recently most investiga-
tors have been initiating therapy with 0.5 gJday
and increasing the dosage, thereafter. Because hy-
percalcemia has been reported occasionally with
0.5 gIday or less [18, 43, 49], it may be safer to
start therapy with 0.25 pg/day. The effects of
1,25(OH)2D3 on target organs such as the gut or the
bone provide the best criteria for the adjustment of
the dose, but it is not feasible from a practical stand-
point to evaluate the changes in intestinal calcium
absorption or bone histology on a repeated and fre-
quent basis. Therefore, it appears that the changes
in concentrations of serum calcium can provide an
alternative guide for the modification of therapy.
Failure to elevate serum calcium concentration by
at least 0.5 mg/dl with any particular dosage given
for 4 to 6 weeks justifies increasing the dosage by
0.25 to 0.5 /Lglday. Such an approach may be used
until serum calcium reaches the normal range (10.0
to 10.5 mgldl). When this is achieved, frequent
monitoring of serum calcium is needed, and if the
latter approaches the hypercalcemic range, a reduc-
tion of the dose or temporary discontinuation of
therapy should be considered. It is our experience
and that of others [36, 39, 49, 58] that the require-
ment of and the tolerance to 1 ,25(OH)2D3 may de-
crease progressively during treatment in many pa-
tients; therefore, reduction of the maintenance dos-
age after a prolonged period of therapy may be
needed.
As many patients with chronic renal failure have
hyperphosphatemia [1], and as the concentration of
serum phosphorus may increase during therapy
with 1,25(OH)2D3, it is mandatory to maintain
serum phosphorus concentrations within the nor-
mal range. At no time should the calcium-phos-
phorus product in blood exceed 55.
Clinical signs and symptoms
Among the most disturbing clinical symptoms of
renal osteodystrophy are muscle weakness [60, 61],
and bone pain [62]. The muscle weakness is a clinical
manifestation of uremic myopathy, which is prob-
ably due to vitamin D deficiency [61]. The exact
cause of bone pain in the uremic patients is not
known, but may be related to the presence of osteo-
malacia and/or osteitis fibrosa. These disturbances
may interfere seriously with the daily activity of the
patients and may even render them totally disabled.
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Improvement in these symptoms appears rapidly af-
ter initiation of therapy with this metabolite. Co-
burn et al [41] reported that skeletal pain began to
improve within 1 to 3 weeks of therapy and that it
disappeared in half of their symptomatic patients.
In addition, the majority of their patients showed
improvement in muscle strength. Pierides et a! [35]
found that treatment with 1 ,25(OH)2D3 improved
muscle strength and decreased bone pain. We also
evaluated the effect of the sterol on these symptoms
in 15 patients [49]. They displayed improvement in
muscle strength after 2 to 5 weeks of treatment, but it
took 6 to 28 weeks of therapy before a decrease in
bone pain became apparent. Thirteen of our pa-
tients had various degrees of physical disability,
and within 6 to 18 months, 11 of them became free
of symptoms and were able to pursue their daily
physical activity. It should be emphasized that pro-
longed therapy may be required in some patients
before such a remarkable improvement in physical
activity occurs. Similar observations were reported
in children [42, 45, 54]. Chesney et a! [54] found that
9 of their 11 patients showed marked improvement
in muscle strength. They described 3 children who
had ceased walking for sevearl months prior to ther-
apy, who began walking within 1 month and were
running within 4 months of treatment.
Another important effect of 1,25(OH)2D3 in ure-
mic children is the increase in growth velocity.
Chesney et al [54] found that height velocity in 8 of
9 uremic children improved markedly during thera-
py with the sterol. The height velocity was in the
third percentile before therapy and rose to the 10th
to 97th percentile after several months of treatment.
These data assign an important role for the use of
I ,25(OH)2D3 in uremic children, as retarded growth
is a very common and serious problem in these pa-
tients [63, 64].
Serum calcium concentration
The most consistent effect of i,25(OH)2D3 in the
uremic and dialysis patients is the elevation in the
serum concentration of calcium [17, 18, 31, 36, 39—
43, 45, 46, 48, 49, 51—54, 56, 58]. Brickman et al [17]
reported the effects of three dosages of the metabo-
lite (0.14, 0.68, and 2.7 pg/day) given for 7 to 15
days to 10 patients. They demonstrated a significant
rise in serum calcium in the patients receiving 0.68
or 2.7 pg/day. The data of other investigators con-
firm these observations [18, 31, 32, 36, 39—43, 45,
46, 48, 49, 51-54, 56, 58] and indicate that most pa-
tients will display a rise in serum calcium after treat-
ment with 0.5 pg/day within 5 days to 4 weeks [41,
43, 45, 51, 52]. Although it is reasonable to assume
that the higher the dosage of the metabolite the
greater the rise in serum calcium concentration, the
available data do not permit an evaluation of a dose-
response curve. Furthermore, many variables in ad-
dition to the dose may modify the calcemic re-
sponse to therapy with 1 ,25(OH)2D3. These may in-
clude duration of treatment, dietary calcium intake,
changes in intestinal absorption of calcium, type of
bone disease and its response to treatment, and
the severity of the state of secondary hyperpara-
thyroidism. Occasionally, the serum calcium con-
centration may fall during the first 1 to 2 weeks
of therapy, probably due to rapid remineralization
of the skeleton; Brickman et a! reported 3 such pa-
tients [53].
Hypercalcemia is a frequent complication of
treatment with 1,25(OH)2D3. It has been reported
that 30 to 67% of the patients treated with this me-
tabolite developed one or more hypercalcemic epi-
sodes during the course of their therapy. The over-
all incidence of one episode was 42%. Hyper-
calcemia occurred with a dosage of 0.5 to 3.0 g/
day of 1,25(OH)2D3 but was more frequent with
dosages of 1.0 to 3.0 sg/day. Certain patients are
more prone to develop hypercalcemia. They in-
clude: (1) patients with osteitis fibrosa and pre-
treatment serum calcium concentrations greater
than 10.5 mg/day; in one such patient, treatment
with a very small dosage of 0.14 pg/day for 2 weeks
produced severe hypercalcemia (14.5 mg/dl) [18],
and (2) patients with "pure" osteomalacia, low
serum concentrations of PTH and absent bone mar-
row fibrosis [41]. Coburn et al [65] reported that all
9 patients who had "pure" osteomalacia developed
hypercalcemia with dosages of less than 0.5 pg/day.
Hypercalcemia may appear at any time during
therapy with 1 ,25(OH)2D3. It usually occurs after 2
to 3 months of therapy but has been reported as
early as 5 days [34] and as late as 6 to 18 months
after treatment. Hypercalcemia has been reported 5
[34] and 6 [31] days after initiation of therapy with
large initial dosages of 2.0 and 2.7 pg/day, respec-
tively. The high starting dose may have been the
cause for the early appearance of hypercalcemia. It
is advisable, therefore, to initiate therapy with small
doses of l,25(OH)2D3 of 0.25 or 0.50 jsg/day. Early
hypercalcemia within 1 to 4 weeks of therapy may
also occur in patients with severe osteitis fibrosa
and pretreatment serum calcium concentrations of
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10.5 mgldl. Extreme caution should be exercised in
the management of such patients with 1 ,25(OH)2D3.
It has been noted that the incidence of hyper-
calcemia increases as the serum alkaline phospha-
tase activity returns to normal [41, 49, 53], and it is
recommended to reduce the dosage of 1 ,25(OH)2D3
when serum alkaline phosphatase activity normal-
izes.
The hypercalcemia is usually mild and asympto-
matic [17, 18, 32, 34—36, 41, 43, 45, 46, 49, 51, 54],
but serum calcium concentrations greater than 13.0
mgldl [18, 49] and occasionally even higher than
15.0 mgldl have been encountered during therapy
with 1,25(0F02D3 [56]. The reported data indicate
that serum calcium concentrations returned to nor-
mal after reduction of the dosage or cessation of
therapy. Occasionally, hypercalcemia may persist
for several weeks after discontinuation of treat-
ment, and two such patients required subtotal para-
thyroidectomy for the control of the hypercalcemia
[18, 39]. The available information indicates that it
is advisable to stop treatment completely rather
than reduce the dosage when hypercalcemia ap-
pears and reinstitute therapy with a smaller dose as
serum calcium concentrations return to normal.
Serum phosphorus concentration
The effect of 1,25(OH)2D3 treatment on the con-
centration of serum phosphorus in uremic or dial-
ysis patients is not consistent. An increase, a de-
crease, or no change have been reported [18, 3 1-34,
36, 39—41, 43, 45, 46, 48, 49, 51—54, 56, 58]. This
variability in the various patient populations may be
related to differences in dietary intake of phos-
phorus and/or the ingestion of phosphate binding
antacids, the dosage of 1,25(OH)2D3, the effect of
the metabolite on intestinal absorption of phos-
phorus, the degree of suppression of the para-
thyroid gland activity, and the status of the reminer-
alization of bone. Monitoring of serum phosphorus
concentrations during therapy with 1,25(OH)2D3 is
mandatory because the development of hyper-
phosphatemia, especially in the face of rising serum
calcium concentration, would result in elevation of
the calcium-phosphorus product and augment the
hazards of soft tissue calcification. If hyper-
phosphatemia occurs and the calcium-phosphorus
product approaches 55, every effort should be made
to control serum phosphorus with phosphate-bind-
ing antacids. If this procedure is not successful, the
dose of 1 ,25(OH)2D3 should be reduced or tempo-
rary cessation of therapy should be considered.
Serum alkaline phosphatase activity
Serum alkaline phosphatase activity usually de-
creases during therapy with 1 ,25(OH)2D3, but sev-
eral months may elapse before the level returns to
normal [18, 35, 36, 41—43, 45, 59, 52—54, 58] (Fig. 1).
We have encountered patients in whom the alkaline
phosphatase activites remained elevated for 10
to 14 months and began to fall only after the ad-
ministration of large dosages of the metabolite
(1.5 to 2.5 g!day). Occasionally, serum alkaline
phosphatase may rise during the initial phase of
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Fig. 1. Changes in serum alkaline phosphatase activities in 15 dialysis patients during therapy with 1,25(OH,12D3 for up to 25 months.
Shaded area represents normal values.
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therapy. Monitoring of serum alkaline phosphatase
could provide an additional guide for the adjustment
of the dosage of l,25(OH)2D3 for two reasons. First,
normalization of serum alkaline phosphatase re-
flects improvement in bone disease, and second, the
occurrence of hypercalcemia increases as serum al-
kaline phosphatase returns to normal.
Serum PTH level
The effect of l,25(OH)2D3 on serum levels of PTH
has been reported in about 120 patients treated with
0.25 to 3.0 tg'day and for periods of 3 weeks to 18
months [18, 35, 39, 43—46, 48, 49, 51—54]. The serum
levels of PTH decreased by 13 to 90% of the control
values in most patients, and in few (30 patients) the
serum levels returned to normal. No change or an
increase in serum PTH concentration was also re-
ported [39, 44, 49, 51, 54]. The variability in these
results may be related to differences in basal serum
levels of PTH reflecting the degree of hyperplasia of
the parathyroid glands, the day to day fluctuation of
serum PTH levels, the dosage and duration of thera-
py, the magnitude of rise in serum calcium, and the
type of PTH assay.
Binswanger Ct al [51] made simultaneous mea-
surements of both the C- and the N-terminal frag-
ments of PTH during therapy with 1,25(OH)2D3.
They found that the effect of the metabolite on
serum PTH levels is better evaluated by the N-ter-
minal fragment because a significant decrease in the
concentration of this moiety occurred without a sig-
nificant change in the levels of the C-terminal frag-
ment. Both Bordier et al [44] and we [49] reported
marked fluctuations in serum levels of PTH during
therapy with l,25(OH)2D3, and it is evident, there-
fore, that single measurements of serum PTH levels
before and after therapy may provide misleading
results.
The reduction in the serum levels of PTH during
therapy with 1,25(OH)2D3 is probably due to the
rise in the concentration of serum calcium. We [49]
found an inverse correlation between the percent
change in serum calcium concentrations and PTH
levels (Fig. 2). Binswanger et al [51] and Brickman
et al [53] could also demonstrate that the fall in
serum PTH levels was related to the rise in serum
calcium concentrations in many of their patients. It
is also possible that l,25(OH)2D3, itself, directly
suppresses the parathyroid gland activity. The
available data in this regard are conflicting and have
been reviewed recently in detail by Golden et al
[66].
Intestinal calciu,n and phosphorus absorption and
urinary calcium
Intestinal calcium absorption increased in most
patients during therapy with l,25(OH)2D3 [17, 30—
33, 35, 37—43, 47, 49, 51]. The effect of the sterol on
this parameter was carefully evaluated by Brickman
et al [67], who found the following: (1) The in-
crement in calcium absorption was most evident
during the first 2 hours after the ingestion of the cal-
cium 47, suggesting that the metabolite exerts its ef-
fect in the duodenum and proximal part of the small
intestine. It should be mentioned that Wecksler,
Mason, and Norman [68] demonstrated specific
cytosol receptors for 1 ,25(OH)2D3 in the human je-
junum and, therefore, the sterol may enhance cal-
cium absorption in this segment of the intestine as
well. (2) There is a dose-response relationship be-
tween 1 ,25(OH)2D3 and intestinal absorption of cal-
cium. (3) The quantity of the sterol required to elicit
an increase in intestinal calcium absorption in the
uremic patient is greater than it is in normal subjects
[17]; this observation suggests that uremia may in-
terfere with the action of the sterol on the gut.
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Fig. 2. Relationship between the changes in the concentration of
serum calcium and the percent change in serum iPTH levels dur-
ing therapy with 1 ,25(OHD3. Each data point represents 1 pa-
tient. From Goldstein et a! [49].
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The mechanisms through which 1 ,25(OH)2D3 en-
hances intestinal absorption are complex [69], and it
has been suggested that the sterol augments the
synthesis of a calcium-binding protein, which facili-
tates the transport of calcium across the gut [70].
Our studies [71] showed that uremic patients have
structural abnormalities of the duodenal mucosa,
including a decrease in the length of the villi and the
crypt of Lieberkühn and distortion of the microvilli.
The treatment with 1 ,25(OH)2D3 restored the struc-
tural integrity of the duodenal mucosa. These de-
rangements may contribute to the defect in calcium
absorption through the reduction of the absorptive
surfaces and interfere with their function.
Brickman et al [40] also studied, with metabolic
balance techniques, the effect of l,25(OH)2D3 on in-
testinal phosphorus absorption in a few uremic pa-
tients. They found the net intestinal absorption of
phosphorous is augmented during treatment with
0.14 to 2.7 Lg/day of l,25(OH)2D3 for 6 to 15 days.
The increase in net phosphorus absorption ranged
from 0.6 to 12.0 (3.9 [SEMI 0.82) mmoles/day.
Interestingly, these authors found a significant cor-
relation between net intestinal absorption of phos-
phorus and that of calcium. This effect of
1,25(OH)2D3 is most probably responsible, at least
partly, for the rise in the concentration of serum
phosphorus that may occur in many uremic patients
treated with this sterol.
The effect of 1 ,25(OH)2D3 on urinary calcium has
been studied in few patients with advanced renal
failure [17, 32, 33, 48] and in three patients with
moderate renal failure [72]. There were either no
changes or modest increments of 20 to 110 mg/day
in urinary calcium excretion.
Bone disease
The effects of 1,25(OH)2D3 on bone histology
have been evaluated in 105 patients [18, 33, 35, 36,
38, 42—44, 46, 50, 51, 54, 55, 58, 73]. It is difficult,
however, to accurately interpret these data for sev-
eral reasons. First, many of the investigators used
qualitative or semiquantitative methods, and others
did not report their results in detail. Second, the
changes in bone histology observed after therapy
may not be entirely due to 1 ,25(OH)2D3 but may re-
flect the considerable variability in bone histology
that exists at various sites of the skeleton [73]. To
overcome this problem, one should obtain two bone
specimens before treatment to evaluate the intrinsic
variability of skeletal histology; differences be-
tween pretreatment and posttreatment values could
be attributed to therapy with l,25(OH)2D3 only
when they are significantly greater than the vari-
ance between the two biopsy specimens obtained
prior to treatment. Third, the diagnosis of osteo-
malacia and the assessment of bone mineralization
were made in most patients (68/93 patients) without
double tetracycline labeling, which is considered
the most appropriate technique for the evaluation of
osteomalacia and bone mineralization [74].
Despite these limitations, a pattern on the effect
of l,25(OH)2D3 emerges from these studies. It ap-
pears that therapy with this metabolite for several
months could be associated with a decrease in bone
resorption [18, 35, 38, 42—44, 50, 55, 58, 73]. Such
an effect was not universal, however [43, 44, 46, 50,
73], and only in a few patients did bone resorption
return to normal [18, 43, 50]. This is not surprising
because such an effect of the metabolite is mediated
through the reduction in the serum levels of PTH,
which have been found to return to normal levels
only in a small percentage of the patients. Endosteal
fibrosis was either markedly reduced or even dis-
appeared during therapy with 1,25(OH)2D3 [18, 35,
44, 50], irrespective of whether the serum levels of
PTH were decreased or not [50]. This finding raises
the possibility that endosteal fibrosis is not entirely
the result of excess PTH but could also be related to
vitamin D deficiency as well.
The data on the effects of 1 ,25(OH)2D3 on uremic
osteomalacia are variable. Coburn et al [65] report-
ed that therapy with this sterol failed to exert a ben-
eficial effect on bone in patients with pure osteo-
malacia and normal serum levels of PTH. Delling et
al [55] also reported no improvement in histologic
parameters in patients with osteomalacia and no
evidence of hyperparathyroid bone disease. On the
other hand, other investigators reported improve-
ment [35, 38, 42, 43, 46, 52, 55, 58, 73] or healing
[38, 50] of osteomalacia in patients who displayed
evidence of both osteomalacia and enhanced bone
resorption. In a study of 12 such patients, we [50],
using double tetracycline labeling, found that osteo-
malacia healed in 7, improved in 3, and did not
change in 2 patients after 6 months of treatment.
Bone x-rays and bone mineral contents
The changes in radiographic appearance of bone
disease during therapy with 1 ,25(OH)2D3 have been
evaluated in a limited number of patients. Evidence
for healing of renal rickets in children [42, 54], or of
osteomalacia in adults as demonstrated by the dis-
appearance of pseudofractures [33, 36], has been
noted. The effects on the x-ray manifestations of
hyperparathyroidism were also evaluated. We [49]
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examined the radiographs of the skull and hands in
10 patients before and after 6 months of therapy.
Four patients showed improvement in the radio-
graphic changes in the skull without concomitant
improvement in those of the hands; in these patients
the serum levels of PTH fell. In two patients who
displayed worsening of the radiographic findings,
serum levels of PTH rose. In the remaining four pa-
tients, the changes in x-rays remained unaltered.
Berl et al [46] found that only 1 of their 15 patients
showed improvement in x-ray signs of bone resorp-
tion after therapy for 3 months.
Only three groups studied the effect of 1,25(OH)2D3
on bone mineral content (BMC) in a total of
23 patients with densitometry [36, 51, 54]. Im-
provement in BMC was reported in 6 patients
[36, 54], 5 of them were children [54]. All of these
patients had overt signs and symptoms of renal
osteodystrophy. On the other hand, Binswanger et
al [51] found no change in BMC in 17 dialysis pa-
tients, without symptomatic bone disease, treated
with 0.2 to 1.0 pg/day 1,25(OH)2D3 for 3 to 8
months.
Although the data on bone x-rays and BMC sug-
gest that these techniques are not valuable tools for
the assessment of the effectiveness of therapy with
I ,25(OH)2D3, the paucity of the information does
not allow a definite conclusion in this regard.
Treatment failure
Failure of therapy with 1 ,25(OH)2D3 to improve
clinical signs and symptoms has been reported [41,
53, 75], and, in one study, this was attributed to
hypophosphatemia [76]. Coburn et al [41] reported
that 11 of 38 patients failed to improve their clinical
symptoms; this could not have been due to hypo-
phosphatemia, because the serum concentrations of
phosphorus were not low. The treatment-failure
group appears to be heterogenous and does not dis-
play a specific biochemical pattern or bone disease.
Although they had higher serum calcium concentra-
tions than did those who responded to treatment,
the serum levels of PTH were normal, moderately
elevated, or very high, and the bone lesions varied
from pure osteomalacia in some to marked osteitis
fibrosa in others. Further analysis of the data, how-
ever, indicates that there are two distinct subgroups
among these patients.
The first group consists of patients with severe
osteitis fibrosa and marked elevation of serum PTH.
In the second group, the patients had normal serum
levels of PTH and pure osteomalacia without evi-
dence of hyperparathyroid bone disease [41, 53,
65], a combination that is difficult to explain unless
these patients have failure of parathyroid gland ac-
tivity and vitamin D deficiency as well. Coburn et al
[65] reported 10 such patients, but the incidence of
this disease in the American uremic population is
not established. Delling et al [55] reported 12 similar
patients and claimed that the incidence of pure
osteomalacia in the European uremic population
may be 20 to 30% [77]. Kanis et al [58] also encoun-
tered patients with similar bone lesions and failure
to respond to therapy with 1 ,25(OH)2D3.
Both of these groups rapidly developed hyper-
calcemia. As this complication requires cessation of
treatment, it would preclude long-term therapy and,
hence, failure to improve the clinical and histologic
abnormailties of renal osteodystrophy. Other mech-
anisms, however, could be responsible for the treat-
ment failure in the patients with pure osteomalacia,
because Coburn et al [41] continued the treatment
of these patients despite mild hypercalcemia and
found no healing of the bone lesions. They postulat-
ed that the low bone turnover is of paramount im-
portance in the failure of therapy. It is possible that
the healing of the pure osteomalacia requires other
vitamin D metabolites such as 25-OH-D3 or
24,25(OH)2D3 in addition to 1 ,25(OH)2D3.
Effects in patients with moderate renalfailure and on
GFR
Data on the effect of 1 ,25(OH)2D3 on the derange-
ments of divalent ion metabolism in patients with
moderate renal failure are limited. Healey et al [72]
treated three patients with creatinine clearances
of 32, 49, and 51 mllmin with 0.5 .tg/day of
1,25(OH)2D3 for 6 months. They found that this
therapy raised serum calcium, reversed the defect
in intestinal calcium absorption, normalized the
serum levels of PTH, and healed the bone disease.
These observations suggest that initiation of thera-
py with 1 ,25(OH)2D3 at the early course of renal
failure could be beneficial for the prevention of the
progression of renal osteodystrophy. Such an ap-
proach could be justified, however, if treatment
with this metabolite has no harmful effect on renal
function.
Theoretically, a deleterious effect of 1,25(OH)2D3
on renal function could be due to a direct action of
the metabolite on the structure or function of the
kidneys or due to other metabolic consequences of
the treatment such as hypercalcemia. Christiansen
et al [48] claimed that the administration of
1 ,25(OH)2D3 to patients with moderate renal failure
produced a significant reduction in GFR from 25.8
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11.5 to 20.1 (SD) 12.8 mi/mm. They attributed
this change to a direct effect of the metabolite on
kidney function. Serious questions could be raised
regarding the significance of their results and the va-
lidity of their conclusions. First, the decrease in the
creatinine clearance in the patients receiving
1,25(OH)2D3 was not significantly greater than it
was in patients treated with 100 g!day of vitamin
D3. Second, they did not perform frequent and se-
quential measurements of creatinine clearance dur-
ing the therapy period, and they relied on a single
determination made at the end of the treatment;
such an approach may lead to false conclusions, for
creatinine clearance fluctuates widely from day to
day. Third, 7 of their 8 patients developed hyper-
calcemia, and this complication might have contrib-
uted to the decrease in creatinine clearance. We
have measured creatinine clearance every 2 weeks
during 6 months of therapy with 1 ,25(OH)2D3 in pa-
tients with moderate renal failure [72]. Hyper-
calcemia did not occur, and GFR remained stable.
Our results and other pertinent data recently re-
viewed [78] do not support the contention that
1 ,25(OH)2D3 has a direct deleterious effect on renal
function. The metabolite could produce a reversible
or permanent fall in GFR, however, if sustained hy-
percalcemia develops during its administration. The
use of the proper dosage, the frequent monitoring of
serum calcium and creatinine concentrations, and
the discontinuation of therapy as hypercalcemia de-
velops are the precautionary measures that should
be followed to reduce the likelihood of a harmful
effect on renal function.
Although the data of Healey et al [72] suggest that
0.5 pg/day of l,25(OH)2D3 is beneficial and safe in
patients with GFR' s of 30 to 51 mllmin and normo-
phosphatemia, it is possible that smaller or larger
dosages may be required by patients with higher or
lower creatinine clearance, respectively. Caution
should be exercised in the use of 1 ,25(OH)2D3 in pa-
tients with GFR's less than 25 mllmin. These pa-
tients may be hyperphosphatemic, and a rise in
blood calcium concentration in the presence of ele-
vated blood phosphorus concentration would result
in an increase in the calcium-phosphorus product to
a hazardous level. In such an eventuality, calcium
deposition may occur in various tissues, including
the renal parenchyma. The latter effect could be as-
sociated with deterioration in renal function.
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